Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

When identified at early stages, most well-differentiated thyroid cancers are readily treated
and yield excellent outcomes. Follicular thyroid cancer (FTC) however, when diagnosed at a …

Background Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor,
trametinib, have been approved for treatment of metastatic melanomas with a BRAF p …

BACKGROUND: The follicular variant of papillary thyroid carcinoma (FVPTC) is the second
most common histotype among papillary thyroid cancers (PTCs). Although the prognosis of …

BRAF gene mutations can be found in approximately 50% of melanomas, but the most
common BRAF mutation leads to substitution at residue 600 of the protein, from valine to …

BRAF gene mutations are identified in about 45% of papillary thyroid carcinomas (PTC) and
represent the most common genetic event in this tumor. Here, we report a case of PTC, solid …

The MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase
signaling pathway) and PI3K/Akt (lipid kinase phoshoinositide-3-kinase signaling pathway) …

BACKGROUND: Up to 80% of thyroid nodules with an indeterminate diagnosis on fine‐
needle aspiration (FNA)(eg,“suspicious for follicular neoplasm”) prove to be benign at the …

The most common BRAF mutation in thyroid cancer is c. 1799T> A (p. Val600Glu), and other
BRAF mutations are rarely reported. We investigated the clinicopathological features of …

With various methods, BRAF mutations have been detected in 73.4% to 87.1% of papillary
thyroid carcinomas (PTCs) in Korea. We assessed the ability of allele-specific polymerase …